熱門資訊> 正文

Oncolytics Biotech GAAP每股收益-0.14加元

2025-11-24 22:18

Oncolytics Biotech, Inc.(ONCY) 0

Oncolytics Biotech (ONCY) press release: Q3 GAAP EPS of -C$0.14.
We ended the third quarter of 2025 with cash and cash equivalents of C$12.35M.

More on Oncolytics Biotech

Oncolytics, FDA agree on phase 3 trial design for elareorep in pancreatic cancer
Oncolytics Biotech entered into $50M at-the-market sales agreement with BTIG
Seeking Alpha’s Quant Rating on Oncolytics Biotech
Historical earnings data for Oncolytics Biotech
Financial information for Oncolytics Biotech

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。